Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors

IntroductionIntegration of biomarkers into clinical management of well-differentiated pancreatic neuroendocrine tumors (PNETs) remains limited due to disease rarity and heterogeneity. By utilizing publicly available genomic databases, we’ve established a large cohort of well-differentiated PNETs for...

Descrición completa

Detalles Bibliográficos

Principais autores:	Leanne M. Brown, Ryan A. Hagenson, Jason M. Sheltzer, John W. Kunstman
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-05-01
Series:	Frontiers in Oncology
Assuntos:	aggressive disease biomarker pancreatic neuroendocrine tumor PNET TP53 mutant
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1757796/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!